Dendreon's Provenge: 'Substantial Evidence of Efficacy'

Echo To All submits: Dendreon's (DNDN) Provenge voted unanimously safe, and a 13-4 vote toward a substantially evidence of efficacy!

The first major hurdle was accomplished, and DNDN should be heading to (at the very least) fair value of 10 or even 20.  While Adam Feuerstein painted at least a $27 price tag, there is still some albeit a little, uncertainty around approval for the only fact that a 3rd party has to approve it. And DNDN can not control that 3rd party.

As I have stated before, the FDA has realized it needed to change the way it views such first in class treatments, and I believe their attitude today demonstrates this even more.

Today's vote may also open up ROW (rest of world) partnership talk, which could give even more upside to the stock.  In my opinion, the cloud of negativity around Provenge prevented such a partnership.  But now there is no such cloud.

Congrats to the PC patients, Dendreon!

Disclosure: Author is long DNDN

Comments

[hpski:]

Again, Echo, we are on the same page. IMO, the business development people at "big pharmas" are now busy dreaming up excuses why they did not make partnership overtures, and at the same time scrambling to make a play. At this point in time, although I don't know anyone at DNDN, IMO, any cross license, co-promotion aggreement, if it is not already being squared away, is not likely till after May 15, then the cost to the assorted Pfizers, Mercks etc. will be considerably higher. Check DNDN's web site - they are already posting for sales positions, so agreements with big pharma most likely will emphasize international, with the prospect of co-promotion in the US, ala BMS & Imclone.

2007 Apr 01 01:55 AM